SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Young who wrote (858)11/22/1997 3:47:00 AM
From: Paul M.  Read Replies (3) of 7041
 
Mike, I agree with you 100%. SGP has billions in cash. 10m is a drop in the bucket for SGP. SGP spends over 700m a year on research and still nets close to 2billion on 6 billion sales. If everyone is interested in equity stakes that SGP has take a look at seprecor. It is developing an antihistamine. This is more in line with SGP core product line and the founders are expatriots from SGP. Not to say SGP's top marketing expertise could not sell 200million+ of Zonas drug. Zona is risky but don't go on the word of Asensio. He is known to pick shorts but he also known to drive a stock down and dump it without telling his fellow shorters.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext